Screening Methods for Liver Cancer

Recruiting in Palo Alto (17 mi)

Overseen byJessica P. Hwang

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

This clinical trial studies the use of surveys, blood testing, and fibroscan in screening for liver fibrosis and liver cirrhosis in new or existing patients of the HOPE clinic seeking usual clinical care. Fibroscan is an imaging procedure of the liver which uses a probe like an ultrasound. Information gathered from this study may help researchers learn more about how to prevent or find liver cancer in patients who are currently receiving care at the HOPE clinic. Early detection of liver cancer may improve survival.

Research Team

Jessica P. Hwang

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults over 18 who can speak and read English or another language with available translation at the HOPE clinic. It's open to new or current patients seeking regular care at the clinic, but pregnant individuals cannot participate.

Inclusion Criteria

Must be able to speak and read English or a language other than English for which there is a translator available on site at the HOPE clinic

I am 18 years old or older.

Must be a new or existing patient of the HOPE clinic seeking usual clinical care

Exclusion Criteria

Known pregnancy at time of recruitment. The HOPE clinic will ask the female patients if they are pregnant, will ask the participants for their last menstrual period (LMP), and/or they will use the urine pregnancy test (UPT) results in their electronic medical records

Treatment Details

Interventions

Clinical Evaluation (Other)
Laboratory Biomarker Analysis (Other)
Liver Ultrasonographic Elastography (Imaging)
Survey Administration (Other)

Trial OverviewThe study is testing how well surveys, blood tests, and a liver scan called Fibroscan can screen for liver fibrosis and cirrhosis in patients. The goal is to find better ways to detect liver cancer early on in people getting care at the HOPE clinic.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Screening (survey, biomarker analysis, fibroscan)Experimental Treatment4 Interventions

Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation, and fibroscan at baseline.